Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DCTH NASDAQ:ESTA NASDAQ:NVCR NASDAQ:SSII On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCTHDelcath Systems$11.02+1.3%$11.52$8.08▼$18.23$385.49M0.85812,569 shs332,243 shsESTAEstablishment Labs$41.27+0.7%$41.28$26.56▼$50.85$1.20B0.85486,158 shs205,800 shsNVCRNovoCure$12.33+2.6%$14.23$10.87▼$34.13$1.38B0.581.55 million shs1.01 million shsSSIISS Innovations International$7.00$6.46$0.32▼$22.42$1.36BN/A45,502 shs32,061 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCTHDelcath Systems0.00%-0.90%+4.06%-32.39%+0.18%ESTAEstablishment Labs0.00%-5.41%-0.17%+21.49%-9.93%NVCRNovoCure0.00%-0.80%+8.92%-27.64%-36.57%SSIISS Innovations International0.00%+0.14%+12.90%+16.86%+699,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDCTHDelcath Systems3.1131 of 5 stars3.52.00.00.03.22.51.3ESTAEstablishment Labs1.6995 of 5 stars3.40.00.00.01.72.50.6NVCRNovoCure3.935 of 5 stars3.32.00.04.52.13.30.0SSIISS Innovations InternationalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDCTHDelcath Systems 3.00Buy$24.50122.32% UpsideESTAEstablishment Labs 2.83Moderate Buy$56.5036.90% UpsideNVCRNovoCure 2.57Moderate Buy$28.79133.46% UpsideSSIISS Innovations International 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest DCTH, NVCR, SSII, and ESTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025ESTAEstablishment LabsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.008/7/2025DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$29.00 ➝ $31.007/25/2025NVCRNovoCureWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$40.00 ➝ $14.507/16/2025ESTAEstablishment LabsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$58.00 ➝ $70.007/9/2025ESTAEstablishment LabsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$38.00 ➝ $47.007/8/2025NVCRNovoCureLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.006/27/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$34.006/23/2025DCTHDelcath SystemsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.006/13/2025ESTAEstablishment LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$48.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDCTHDelcath Systems$70.24M5.49N/AN/A$2.15 per share5.13ESTAEstablishment Labs$177.42M6.74N/AN/A$1.90 per share21.72NVCRNovoCure$630.16M2.19N/AN/A$3.33 per share3.70SSIISS Innovations International$27.62M49.06N/AN/A$0.08 per share87.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDCTHDelcath Systems-$26.39M$0.05220.40N/AN/A3.18%6.91%5.80%11/14/2025 (Estimated)ESTAEstablishment Labs-$84.60M-$3.05N/AN/AN/A-49.89%-224.34%-25.53%11/6/2025 (Estimated)NVCRNovoCure-$168.63M-$1.56N/AN/AN/A-27.13%-47.74%-13.79%10/29/2025 (Estimated)SSIISS Innovations International-$19.15MN/A0.00∞N/A-40.20%-40.41%-20.80%N/ALatest DCTH, NVCR, SSII, and ESTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ESTAEstablishment Labs-$0.54-$0.57-$0.03-$0.57$50.80 million$51.30 million8/6/2025Q2 2025DCTHDelcath Systems$0.02$0.07+$0.05$0.07$22.84 million$24.16 million7/24/2025Q2 2025NVCRNovoCure-$0.39-$0.36+$0.03-$0.36$153.87 million$158.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDCTHDelcath SystemsN/AN/AN/AN/AN/AESTAEstablishment LabsN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/ASSIISS Innovations InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDCTHDelcath SystemsN/A10.889.87ESTAEstablishment Labs9.712.841.67NVCRNovoCure0.281.451.39SSIISS Innovations InternationalN/A2.591.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDCTHDelcath Systems61.12%ESTAEstablishment Labs72.91%NVCRNovoCure84.61%SSIISS Innovations InternationalN/AInsider OwnershipCompanyInsider OwnershipDCTHDelcath Systems17.40%ESTAEstablishment Labs11.09%NVCRNovoCure5.52%SSIISS Innovations InternationalN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDCTHDelcath Systems6034.98 million28.71 millionOptionableESTAEstablishment Labs1,01828.97 million25.66 millionOptionableNVCRNovoCure1,488111.80 million105.63 millionOptionableSSIISS Innovations International4193.59 millionN/AN/ADCTH, NVCR, SSII, and ESTA HeadlinesRecent News About These CompaniesSS Innovations International (NASDAQ:SSII) Stock Price Up 17.1% - Still a Buy?August 24, 2025 | marketbeat.comSS Innovations International (NASDAQ:SSII) Shares Gap Down - Time to Sell?August 20, 2025 | marketbeat.comSS Innovations International (NASDAQ:SSII) Shares Gap Up - Should You Buy?August 16, 2025 | marketbeat.comSS Innovations International Inc. Stock Grades | SSII | Barron'sAugust 15, 2025 | barrons.comSS Innovations International (NASDAQ:SSII) Stock Price Down 8% - What's Next?August 12, 2025 | marketbeat.comSs Innovations (SSII) Q2 Revenue Up 122%August 8, 2025 | aol.comASS Innovations Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | prismmediawire.comPSS Innovations Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comSS Innovations Announces Completion of World’s First Intercontinental Robotic Cardiac TelesurgeryJuly 23, 2025 | finance.yahoo.comSS Innovations Announces Completion of World's First Intercontinental Robotic Cardiac TelesurgeryJuly 22, 2025 | prismmediawire.comPSS Innovations Announces Completion of World's First Intercontinental Robotic Cardiac TelesurgeryJuly 22, 2025 | globenewswire.comSSII - SS Innovations International Inc Ownership | MorningstarJuly 17, 2025 | morningstar.comMSS Innovations Surpasses Milestone of 100 Installations of the SSi Mantra Surgical Robotic SystemJuly 15, 2025 | prismmediawire.comPSS Innovations Announces Completion of World's First Robotic Telesurgery for Weight Loss with the Company's SSi Mantra 3 Surgical Robotic SystemJuly 10, 2025 | prismmediawire.comPSS Innovations Announces Completion of World's First Robotic Telesurgery for Weight Loss with the Company's SSi Mantra 3 Surgical Robotic SystemJuly 10, 2025 | globenewswire.comSS Innovations: A Speculative Bet On Robotic SurgeriesJune 19, 2025 | seekingalpha.comSS Innovations Announces Successful Completion of First Robotic Cardiac Surgery in the Western Hemisphere Utilizing the Company's SSi Mantra 3 Surgical Robotic SystemJune 16, 2025 | prismmediawire.comPSS Innovations Announces Successful Completion of First Robotic Cardiac Surgery in the Western Hemisphere Utilizing the Company's SSi Mantra 3 Surgical Robotic SystemJune 16, 2025 | globenewswire.comSS Innovations Surpasses Milestone of 4,000 Robotic Surgeries Successfully Performed with the SSi Mantra Surgical Robotic SystemMay 27, 2025 | prismmediawire.comPSS Innovations Surpasses Milestone of 4,000 Robotic Surgeries Successfully Performed with the SSi Mantra Surgical Robotic SystemMay 27, 2025 | globenewswire.comSS Innovations Reports First Quarter 2025 Financial ResultsMay 14, 2025 | prismmediawire.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDCTH, NVCR, SSII, and ESTA Company DescriptionsDelcath Systems NASDAQ:DCTH$11.02 +0.14 (+1.29%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$10.86 -0.16 (-1.44%) As of 08/29/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Establishment Labs NASDAQ:ESTA$41.27 +0.27 (+0.66%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$40.40 -0.88 (-2.12%) As of 08/29/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.NovoCure NASDAQ:NVCR$12.33 +0.31 (+2.58%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$12.32 -0.01 (-0.04%) As of 08/29/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.SS Innovations International NASDAQ:SSII$7.00 0.00 (0.00%) As of 08/29/2025 04:00 PM EasternAVRA Medical Robotics, Inc. develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc. and changed its name to AVRA Medical Robotics, Inc. in November 2015. AVRA Medical Robotics, Inc. was founded in 2015 and is based in Orlando, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
